AVALO THERAPEUTICS, INC.: goodwill carrying amount
Goodwill carrying amount for AVALO THERAPEUTICS, INC. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All AVALO THERAPEUTICS, INC. financial histories
What this measure means
Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.
Exact concept: us-gaap:Goodwill. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2016-12-31 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-12-31 | 10,502,000 | USD | 2026-03-23 | 10-K · 0001534120-26-000011 |
| At date | 2024-12-31 | 10,502,000 | USD | 2026-03-23 | 10-K · 0001534120-26-000011 |
| At date | 2023-12-31 | 10,502,000 | USD | 2025-03-20 | 10-K · 0001628280-25-013986 |
| At date | 2022-12-31 | 14,409,000 | USD | 2025-03-20 | 10-K · 0001628280-25-013986 |
| At date | 2021-12-31 | 14,409,000 | USD | 2023-03-29 | 10-K · 0001628280-23-009630 |
| At date | 2020-12-31 | 14,409,000 | USD | 2022-03-02 | 10-K · 0001628280-22-004671 |
| At date | 2019-12-31 | 14,409,088 | USD | 2021-03-08 | 10-K · 0001628280-21-004162 |
| At date | 2018-12-31 | 14,409,088 | USD | 2020-03-11 | 10-K · 0001628280-20-003395 |
| At date | 2017-12-31 | 12,290,247 | USD | 2020-03-11 | 10-K · 0001628280-20-003395 |
| At date | 2016-12-31 | 0 | USD | 2019-03-18 | 10-K · 0001628280-19-003078 |
Related financial histories
- AVALO THERAPEUTICS, INC.: total assets
- AVALO THERAPEUTICS, INC.: total liabilities
- AVALO THERAPEUTICS, INC.: stockholders equity
- AVALO THERAPEUTICS, INC.: cash and cash equivalents
- AVALO THERAPEUTICS, INC.: net income or loss
- AVALO THERAPEUTICS, INC.: operating cash flow
- AVALO THERAPEUTICS, INC.: capital expenditure payments
- AVALO THERAPEUTICS, INC.: revenue
- AVALO THERAPEUTICS, INC.: contract revenue excluding tax
- AVALO THERAPEUTICS, INC.: financing cash flow
- AVALO THERAPEUTICS, INC.: investing cash flow
- AVALO THERAPEUTICS, INC.: retained earnings or deficit
- AVALO THERAPEUTICS, INC.: basic weighted-average shares
- AVALO THERAPEUTICS, INC.: diluted weighted-average shares
- AVALO THERAPEUTICS, INC.: basic earnings per share
- AVALO THERAPEUTICS, INC.: diluted earnings per share
- AVALO THERAPEUTICS, INC.: income tax expense or benefit
- AVALO THERAPEUTICS, INC.: net property, plant and equipment
- AVALO THERAPEUTICS, INC.: share-based compensation expense
- AVALO THERAPEUTICS, INC.: operating income or loss
- AVALO THERAPEUTICS, INC.: current assets
- AVALO THERAPEUTICS, INC.: current liabilities
- AVALO THERAPEUTICS, INC.: current accounts payable
- AVALO THERAPEUTICS, INC.: net finite-lived intangible assets
- AVALO THERAPEUTICS, INC.: operating expenses
- AVALO THERAPEUTICS, INC.: net inventory
- AVALO THERAPEUTICS, INC.: research and development expense
Inspect the source
- Entity
- AVALO THERAPEUTICS, INC. / CIK 0001534120
- Captured
- 2026-09-20T09:16:35.394Z
- SEC response SHA-256
c27cef5388033067af62e0489a1b2af90f086713b680df0f63e0f63ad2ea1ca3
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001534120.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))